Pharmaceutical Technology

NOVEMBER 9, 2022

In the EU however, two years later, the European Commission awarded a conditional marketing authorisation for Roctavian. Reimbursement has been a major obstacle in the EU for expensive gene therapies, including bluebird bio’s beta-thalassemia therapy Zynteglo. million price tag. million ($1.5 million ($1.8 million at the time).

Safety 111

Safety Pharmaceutical Patients Medicine 111

Pharmaceutical Technology

JULY 14, 2022

Centralised incentives are also in place across Europe, as well as at the national level in some EU states. Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK).

Medicine 59

Medicine Marketing Specialization Pharma 59

Pharmaceutical Technology

DECEMBER 5, 2022

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. In most EU and Commonwealth countries, including the UK, New Zealand and Australia, cannabinoids are legal for medical use.

Medical 98

Medical Specialization Marketing Leads 98

pharmaphorum

AUGUST 25, 2022

Johnson & Johnson has its first worldwide regulatory approval – in the EU – for Tecvayli, one of two much-anticipated bispecific antibodies the drugmaker has developed for patients with multiple myeloma. Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.

FDA 96

FDA Marketing Safety Patients 96

pharmaphorum

AUGUST 26, 2022

BioMarin will no doubt have an eye on the earlier experience of bluebird bio, which secured EU approval for rare disease gene therapy Zynteglo (betibeglogene autotemcel) in 2019 for beta thalassaemia with a price tag of around €1.6 million spread over five years.

FDA 109

FDA Marketing Competition Patients 109